Heart failure drug withdrawal trial aims to simplify treatment
NCT ID NCT07489547
First seen Apr 10, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study looks at whether people with stable heart failure whose heart function has improved can safely stop taking a specific medication called a mineralocorticoid antagonist (MRA). About 90 participants will either continue their usual medication or receive a placebo for 24 weeks. The goal is to see if stopping the drug causes any decline in heart function or worsening of heart failure symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital de Clínicas de Porto Alegre
RECRUITINGPorto Alegre, Rio Grande do Sul, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.